Literature DB >> 15642410

Influence of enantiomers of 1-naphthylalanine in position 2 of VAVP and dVAVP on their pharmacological properties.

Izabela Derdowska1, Adam Prahl, Wioleta Kowalczyk, Marcin Janecki, Samed Melhem, Henryk I Trzeciak, Bernard Lammek.   

Abstract

In this study, we described the synthesis and some pharmacological properties of four new analogues of arginine vasopressin (AVP). Two peptides are substituted in position 2 with L-1-naphthylalanine (L-1-Nal) or its D-enantiomer and in position 4 with valine. In the further two compounds, we combined the above modifications with placement into position 1 of 3-mercaptopropionic acid residue (Mpa). All new peptides were tested for vasopressor and antidiuretic activities. We also estimated the uterotonic activities of these compounds in vitro. Urine samples prior and after peptide administration were analyzed for electrolytes excretion. All analogues are potent oxytocin antagonists. One of them, namely [L-1-Nal2,Val4]AVP, which appears practically not to interact with V1a and V2 receptors, is exceptionally selective. Our results open new possibilities for the design of very potent and selective oxytocin antagonists in vitro.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15642410     DOI: 10.1016/j.ejmech.2004.09.011

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  Azetidinones as vasopressin V1a antagonists.

Authors:  Christophe D Guillon; Gary A Koppel; Michael J Brownstein; Michael O Chaney; Craig F Ferris; Shi-Fang Lu; Karine M Fabio; Marvin J Miller; Ned D Heindel; David C Hunden; Robin D G Cooper; Stephen W Kaldor; Jeffrey J Skelton; Bruce A Dressman; Michael P Clay; Mitchell I Steinberg; Robert F Bruns; Neal G Simon
Journal:  Bioorg Med Chem       Date:  2006-12-23       Impact factor: 3.641

2.  Design, synthesis and biological activity of new neurohypophyseal hormones analogues conformationally restricted in the N-terminal part of the molecule. Highly potent OT receptor antagonists.

Authors:  Anna Kwiatkowska; Monika Ptach; Lenka Borovičková; Jiřina Slaninová; Bernard Lammek; Adam Prahl
Journal:  Amino Acids       Date:  2011-10-29       Impact factor: 3.520

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.